- A large monument is in southeastern Mexico.
- The site is called Aguada Fénix.
- It is nearly a mile long.
- It is a quarter-mile wide and 30 to 50 feet high.
- The monument dates to 1,000 BCE.
- Archaeologists saw features with lidar in 2017.
- They found jade axes and carved ornaments.
- A cross-shaped pit had pigments placed by direction.
Difficult words
- researcher — A person who studies something.Researchers
- discovery — Finding something new or unknown.
- site — Place where something happens.
- important — Something that matters a lot.
- ritual — A special act done in a set way.rituals
- found — To discover or see something.
- understand — To know what something means.
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- What do you think about discoveries like this?
- Why is it important to study early cultures?
- How do you feel about the size of the buildings?
Related articles
Decaying dark matter may explain early giant black holes
Researchers propose that tiny energy from decaying dark matter changed gas chemistry in the first galaxies. This could let some gas clouds collapse directly into massive black holes, helping to explain early observations by the James Webb Space Telescope.
How mangroves survive saltwater
Scientists studied mangrove trees to learn why some plants tolerate repeated saltwater flooding. They found small cells and thicker cell walls help mangroves stay strong in salty, waterlogged conditions and suggest this could help make crops more salt-tolerant.
Community Playlist Supports Nate Matias’s Charity Ride
Global Voices community members built a playlist to support Nate Matias as he cycled the equivalent of 10,000 meters in elevation over three days to raise money for Global Voices. Contributors explained their song choices and honoured the ride’s Nepalese roots.
New oral drug approved for sleeping sickness
European regulators approved Acoziborole, a single-dose oral treatment for sleeping sickness after successful trials in the DRC and Guinea. Sanofi will donate doses to WHO, but national approvals and vector control are still needed to reach elimination goals.